Literature DB >> 19927350

New method for calcium on the ADVIA analyzer is free from interference of gadolinium-type contrast agents.

Pradip Datta1, Amitava Dasgupta.   

Abstract

Recently, Siemens Diagnostics released a new calcium assay (CA_2) based on complex formation of calcium with Arsenazo III dye for use on the three automated, random access ADVIA Chemistry analyzers (1650, 2400, and 1200). We evaluated this method for analytical performance as well as potential interference from gadolinium-containing magnetic contrast agents. With Siemens Chemistry serum and urine controls, 2-levels each, the imprecision for the new method was (n=40 each): within-run and total CV of <2.2 and <3.8%, respectively, over all three platforms. The analytical range/linearity of the method (all three systems) was 1-16 mg/dl (serum or plasma) and 1-32 mg/dl (urine). The new method on all three platforms correlated well with a reference (Inductively Coupled Plasma Atomic Emission Spectroscopy) method (n=61, range 4.03-10.30 mg/dl). The ADVIA 1650 CA_2 method also correlated well with the Roche Modular system((R)) Calcium method. The new method showed <10% interference with unconjugated or conjugated bilirubin (50 mg/dl), hemoglobin (1,000 mg/dl), lipids (1,000 mg/dl), and two magnetic resonance contrast agents containing Gadolinium (OptiMARK((R)) 1 mmol/l and Omniscan 1.5 mmol/l). On the contrary, the Roche Calcium method showed significant negative interference with gadolinium-containing contrast agents. We conclude that the ADVIA Ca_2 method can measure serum, plasma, or urine calcium concentrations accurately and is also free from interferences of gadolinium-containing agents.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19927350      PMCID: PMC6649172          DOI: 10.1002/jcla.20353

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  16 in total

Review 1.  Review of calcium methodologies.

Authors:  B Zak; E Epstein; E S Baginski
Journal:  Ann Clin Lab Sci       Date:  1975 May-Jun       Impact factor: 1.256

2.  Arsenazo III: an improvement of the routine calcium determination in serum.

Authors:  J W Janssen; A R Helbing
Journal:  Eur J Clin Chem Clin Biochem       Date:  1991-03

Review 3.  Current management strategies for hypercalcemia.

Authors:  Martin Pecherstorfer; Karin Brenner; Niklas Zojer
Journal:  Treat Endocrinol       Date:  2003

4.  Interference of gadolinium-containing contrast-enhancing agents with colorimetric calcium laboratory testing.

Authors:  Andrea Löwe; Thomas Balzer; Uta Hirt
Journal:  Invest Radiol       Date:  2005-08       Impact factor: 6.016

5.  Spurious hypocalcemia after Omniscan- or OptiMARK-enhanced magnetic resonance imaging: an algorithm for minimizing a false-positive laboratory value.

Authors:  Jane Emerson; Gerald Kost
Journal:  Arch Pathol Lab Med       Date:  2004-10       Impact factor: 5.534

Review 6.  Medical treatment of malignancy-associated hypercalcemia.

Authors:  F Lumachi; A Brunello; A Roma; U Basso
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

7.  Clinical and economic impact of falsely decreased calcium values caused by gadoversetamide interference.

Authors:  Manish J Gandhi; Vamsidhar R Narra; Jeffrey J Brown; Amy Guo; Daniel S Grosu; Curtis A Parvin; Mitchell G Scott
Journal:  AJR Am J Roentgenol       Date:  2008-03       Impact factor: 3.959

8.  Model for predicting the impact of gadolinium on plasma calcium measured by the o-cresolphthalein method.

Authors:  Hyunseok Peter Kang; Mitchell G Scott; Bonnie N Joe; Vamsi Narra; Jay Heiken; Curtis A Parvin
Journal:  Clin Chem       Date:  2004-02-12       Impact factor: 8.327

Review 9.  Milk-alkali syndrome.

Authors:  Boris I Medarov
Journal:  Mayo Clin Proc       Date:  2009-03       Impact factor: 7.616

10.  Gadolinium magnetic resonance contrast agents produce analytic interference in multiple serum assays.

Authors:  Kerry A S Proctor; Lokinendi V Rao; William L Roberts
Journal:  Am J Clin Pathol       Date:  2004-02       Impact factor: 2.493

View more
  3 in total

1.  Fasting urinary calcium-to-creatinine and oxalate-to-creatinine ratios in dogs with calcium oxalate urolithiasis and breed-matched controls.

Authors:  E Furrow; E E Patterson; P J Armstrong; C A Osborne; J P Lulich
Journal:  J Vet Intern Med       Date:  2015-01-10       Impact factor: 3.333

2.  Urinary metals in a spontaneous canine model of calcium oxalate urolithiasis.

Authors:  Eva Furrow; Molly E McCue; Jody P Lulich
Journal:  PLoS One       Date:  2017-05-03       Impact factor: 3.240

Review 3.  Interference of medical contrast media on laboratory testing.

Authors:  Giuseppe Lippi; Massimo Daves; Camilla Mattiuzzi
Journal:  Biochem Med (Zagreb)       Date:  2014-02-15       Impact factor: 2.313

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.